Author

Number of items: 279.
Article
  • Treatment and management approaches for ketamine misuse: A systematic review of medical interventions. (2026) Alessio Mosca, Stefania Chiappini, Andrea Miuli, John Martin Corkery, Tommaso Piro, Rita Allegretti, Nicola Ciraselli, Carlotta Marrangone, Nicolò Schifano, Mauro Pettorruso, Giovanni Martinotti and Fabrizio Schifano picture_as_pdf
  • GLP-1 and dual GIP/GLP-1 receptor agonists’ psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill–informed, systematic, evaluation. (2026) Fabrizio Schifano, Maria Antonietta De Luca, Stefania Bonaccorso, Davide Arillotta, Giuseppe Floresta, Giovanni Martinotti, Gabriele Duccio Papanti, John Martin Corkery, Stefania Chiappini and Amira Guirguis picture_as_pdf
  • Crawling into the Unknown: Unveiling Novel Psychoactive Substances (NPSs) in the post pandemic era utilizing the NPSfinder®. (2026) Elena Deligianni, Alessandro Vento, Georgios Papazisis, Antonis Goulas, Lisa Lione and Fabrizio Schifano picture_as_pdf
  • Possible signals of ocular disorders associated with gabapentinoids: A three-arm study. (2026) Mya Murray, Amira Guirguis, Paul Deslandes, John Martin Corkery, Stefania Chiappini, Mariacristina Parravano and Fabrizio Schifano picture_as_pdf
  • Psychopharmacology of Methamphetamine in Relation to the United Kingdom Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin. (2026) Amira Guirguis, Arianna Giorgetti, Jegak Seo, John Martin Corkery and Fabrizio Schifano
  • Psychopharmacology of Methamphetamine in Relation to UK Sentencing Guidance: Comparative Analysis with Amphetamine, Cocaine and Heroin. (2026) Amira Guirguis, Arianna Giorgetti, Jegak Jegak, John Martin Corkery and Fabrizio Schifano picture_as_pdf
  • Tolazoline, an alpha-adrenergic antagonist, may also block xylazine at off-target sites as inferred from molecular docking. (2026) Giuseppe Floresta, Vincenzo Patamia, Alberto Granzotto, Davide Arillotta, Gabriele Duccio Papanti, Amira Guirguis, John Martin Corkery, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano picture_as_pdf
  • Deaths involving gabapentin and pregabalin, Scotland, 2000-2024: a descriptive account. (2026) John Martin Corkery, Amira Guirguis and Fabrizio Schifano picture_as_pdf
  • Health-Related Quality of Life in Previous Versus Current Opiate Users Receiving HCV Therapy: Registry-Based Evidence. (2026) Michael Specka, Stefan Christensen, Peter Buggisch Buggisch, Renate Heyne, Uwe Naumann, Hartwig Klinker, Ralph Link, Christiane Sybille Schmidt, Bernd Schulte, Jens Reimer, Fabrizio Schifano, Heiner Wedemeyer and Norbert Scherbaum picture_as_pdf
  • Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment. (2026) Stefania Chiappini, John Martin Corkery, Amira Guirguis, Alessio Mosca, Mya Murray, Davide Arillotta, Luigi Dattoli, Giovanni Martinotti, Stefania Bonaccorso, Fabrizio Schifano and Nicolo Schifano
  • Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database. (2026) Mya Murray, Fabrizio Schifano, Stefania Chiappini, John Martin Corkery and Amira Guirguis picture_as_pdf
  • Reply to comment on: “Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists: an examination of the FAERS database”. (2026) Mya Murray, Fabrizio Schifano, Stefania Chiappini, John Martin Corkery and Amira Guirguis picture_as_pdf
  • Psychoactive Synthetic Adulterants in Tablets Sold as MDMA after the COVID-19 Pandemic : Implications for Central Effects. (2026) Maria Antonietta De Luca, Cristina Miliano, Amanda Roxburgh, Myfanwy Graham, Francesca Caria, Amira Guirguis, Fabrizio Schifano, Suzanne Nielsen, Nicola Simola and Giulia Costa picture_as_pdf
  • Ketamine-related deaths registered in Scotland 2013-2024. (2026) John Martin Corkery, Amira Guirguis and Fabrizio Schifano
  • Novel psychoactive substances (NPS) as a risk factor for psychosis: a systematic review of the literature. (2025) Alessio Mosca, Gianluca Mancusi, Stefania Chiappini, Andrea Miuli, Clara Cavallotto, John Martin Corkery, Gilberto Di Petta, Arianna Pasino, Monica Chiara Santovito, Carlotta Marrangone, Maria Chiara Vicinelli, Mauro Pettorruso, Giovanni Martinotti and Fabrizio Schifano picture_as_pdf
  • Managing Dual Diagnosis Patients and the Importance of Assessing Capacity: Data from London Inpatient Services. (2025) Iain Hyndman, Angelo Ricciardi, Olesya Ajnakina, Christian Lowe, Cemile Kalkan, Sofia Mota, Christos Theleritis, Stefano Ferracuti, Stefania Bonaccorso and Fabrizio Schifano
  • Possible eye disorders in children prenatally exposed to either methadone or buprenorphine in comparison with other medications; an examination of the Food and Drug Administration (FDA) pharmacovigilance database. (2025) Stefania Chiappini, Laura Orsolini, John Martin Corkery, Amira Guirguis, Alessio Mosca, Davide Arillotta, Giovanni Martinotti and Fabrizio Schifano picture_as_pdf
  • Focus on ‘Psychiatry and Addiction: A Multi-Faceted Issue’. (2025) Fabrizio Schifano, Norbert Scherbaum and Giovanni Martinotti
  • Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes. (2025) Alessio Mosca, Stefania Chiappini, Andrea Miuli, Clara Cavallotto, Mauro Pettorruso, Giovanni Martinotti and Fabrizio Schifano
  • Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and ‘Smart Drug’ Use and Misuse. (2025) Fabrizio Schifano, Stefania Bonaccorso, Davide Arillotta, John Martin Corkery, Giuseppe Floresta, Gabriele Duccio Papanti and Amira Guirguis
  • “Becoming Your Own Psychologist”: Novel Psychoactive Substances (NPSs) for Mood and Anxiety Disorder Self-Medication. (2025) Tayler Holborn, Fabrizio Schifano, Emma Smith and Paulo Deluca
  • Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: a systematic review and case-series report. (2025) John Martin Corkery, Caroline S Copeland and Fabrizio Schifano
  • Adverse Drug Reactions Associated with Concomitant Use of Calcium Channel Blockers and Cocaine: An Analysis of FDA Adverse Events Reporting System Data. (2025) Stefania Chiappini, Alessio Mosca, Duccio G Papanti, John Martin Corkery, Amira Guirguis, Davide Arillotta, Giovanni Martinotti and Fabrizio Schifano picture_as_pdf
  • Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues. (2025) Fabrizio Schifano, Stefania Bonaccorso, Davide Arillotta, Amira Guirguis, John Martin Corkery, Giuseppe Floresta, Gabriele Duccio Papanti Pelletier, Norbert Scherbaum and Nicolò Schifano
  • Psychological and Clinical Parameters as Predictors of Relapse in Alcohol-Dependent Patients During and After Extensive Inpatient Rehabilitation Treatment. (2025) Josef Rabl, Dieter Geyer, Katharina Steiner, Fabrizio Schifano and Norbert Scherbaum
  • Xylazine as an emerging new psychoactive substance; focuses on both 5‐HT 7 and κ‐opioid receptors' molecular interactions and isosteric replacement. (2025) Giuseppe Floresta, Alberto Granzotto, Vincenzo Patamia, Davide Arillotta, Gabriele D. Papanti, Amira Guirguis, John M. Corkery, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano
  • The Use of Novel Stimulants in ADHD Self-Medication: A Mixed Methods Analysis. (2025) Tayler Holborn, Fabrizio Schifano, Emma Smith and Paolo Deluca
  • Over-the-counter Psychosis : A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis. (2025) Alessio Mosca, Stefania Chiappini, Gianluca Mancusi, Andrea Miuli, Carlotta Marrangone, Rita Allegretti, Serena Panichella, Clara Cavallotto, John Martin Corkery, Mauro Pettorruso, Giovanni Martinotti and Fabrizio Schifano
  • From Veterinary Medicine to Illicit Drug Supply: Utilising Social Media to Explore the Rising Emergence of Veterinary Medicines in Human Health. (2025) Josie Dunn, Fabrizio Schifano, Ed Dudley, Davide Arillotta and Amira Guirguis picture_as_pdf
  • Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders : A pharmacovigilance perspective. (2025) S Chiappini, A Guirguis, N Schifano, J Corkery, F Semeraro, A Mosca, G D'Andrea, G D Papanti, D Arillotta, G Floresta, G Martinotti and F Schifano
  • An Update on Deaths in the United Kingdom from 'Poppers' (Alkyl Nitrites), with a Particular Focus on 'Swallowing' Fatalities. (2025) John Martin Corkery, Caroline Copeland, Stephen Ream, Peter Streete and Fabrizio Schifano
  • 2025: A Bright Year Ahead for Future Pharmacology. (2025) Fabrizio Schifano picture_as_pdf
  • Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs. (2024) Patrik Roser, Mona Brunstein, Michael Specka, Jörg Timm, Stefan Kühnhold, Fabrizio Schifano, Udo Bonnet and Norbert Scherbaum
  • Postmortem findings of organ damage in novel psychoactive substances users: a comprehensive review. (2024) Beatrice Benedetti, Celeste Conte, Eva Bergamin, Riccardo Di Santo, Gabriele Ciasca, John M Corkery, Marta Bassi, Giorgia Corli, Sabrine Bilel, Fabrizio Schifano, Matteo Marti and Fabio De-Giorgio
  • Neuropsychological Abnormalities Associated with Alcohol Dependence During Long-Term Rehabilitation Treatment of German Inpatients. (2024) Josef Rabl, Dieter Geyer, Dario Kroll, Fabrizio Schifano and Norbert Scherbaum picture_as_pdf
  • Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. (2024) Stefania Chiappini, Pietro Domenico Gramuglia, Alessio Mosca, Clara Cavallotto, Andrea Miuli, John Martin Corkery, Amira Guirguis, Fabrizio Schifano and Giovanni Martinotti
  • Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain. (2024) Chiara Montemitro, Alessio Mosca, Stefania Chiappini, Andrea Miuli, Fabrizio Schifano, Maria Josè Gordillo Montano, Cristina Merino Del Villar, Rita Allegretti, Carlotta Marrangone, Gilberto Di Petta, Domenico De Berardis, Mauro Pettorruso and Giovanni Martinotti
  • Evaluation of E-Cigarette Use in Opioid-Dependent Patients in Maintenance Treatment. (2024) Josef Rabl, Michael Specka, Udo Bonnet, Özge Irtürk, Fabrizio Schifano and Norbert Scherbaum
  • Exploring Human Misuse and Abuse of Veterinary Drugs: A Descriptive Pharmacovigilance Analysis Utilising the Food and Drug Administration’s Adverse Events Reporting System (FAERS). (2024) Josie Dunn, Fabrizio Schifano, Ed Dudley and Amira Guirguis
  • Exploring the Confluence of Animal Medicine and its Implications for Human Health : A Systematic Literature Review. (2024) Josie Dunn, Fabrizio Schifano, Ed Dudley and Amira Guirguis
  • Piperazine Abuse and Psychosis: A Systematic Review of the Literature. (2024) Alessio Mosca, Stefania Chiappini, Andrea Miuli, Gianluca Mancusi, Clara Cavallotto, John Martin Corkery, Livia Miotti, Mauro Pettorruso, Giovanni Martinotti and Fabrizio Schifano
  • New trends of drug abuse in custodial settings: a systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances. (2024) Stefania Chiappini, Giorgia Vaccaro, Alessio Mosca, Andrea Miuli, Gianfranco Stigliano, Giulia Stefanelli, Giulia Giovannetti, Rosalba Carullo, Giacomo d'Andrea, Francesco Di Carlo, Clara Cavallotto, Mauro Pettorruso, Gilberto Di Petta, John Martin Corkery, Amira Guirguis, Jacqueline L. Stair, Giovanni Martinotti, Seena Fazel and Fabrizio Schifano picture_as_pdf
  • Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. (2024) Davide Arillotta, Giuseppe Floresta, G. Duccio Papanti Pelletier, Amira Guirguis, John Martin Corkery, Giovanni Martinotti and Fabrizio Schifano
  • Exploring Vaping Patterns and Weight Management-Related Concerns among Adolescents and Young Adults: A Systematic Review. (2024) Srishti Mohapatra, Sharadha Wisidagama and Fabrizio Schifano
  • Exploring the Association Between Suicidal Thoughts, Self-Injury, and GLP-1 Receptor Agonists in Weight Loss Treatments: Insights from Pharmacovigilance Measures and Unmasking Analysis. (2024) Amira Guirguis, Stephania Chiappini, P G Duccio Papanti, Rachel Vickers-Smith, Daniel Harris, John Corkery, Davide Arillotta, Giuseppe Floresta, Giovanni Martinotti and Fabrizio Schifano
  • Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions. (2024) Giuseppe Floresta, Davide Arillotta, Valeria Catalani, G. Duccio Papanti Pelletier, John Corkery, Amira Guirguis and Fabrizio Schifano
  • Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. (2024) Anthony Mullin, Mark Scott, Giorgia Vaccaro, Giuseppe Floresta, Davide Arillotta, Valeria Catalani, John M Corkery, Jacqueline L Stair, Fabrizio Schifano and Amira Guirguis
  • 2023: the best year ever for Future Pharmacology (and even better years to come). (2024) Fabrizio Schifano description
  • The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database. (2023) Sara Baldini, Ahmed Khattak, Paolo Capogrosso, Gabriele Antonini, Federico Dehò, Fabrizio Schifano and Nicolò Schifano picture_as_pdf
  • Could Cariprazine Be a Possible Choice for High Functioning Autism? A Case Report. (2023) Andrea Miuli, Carlotta Marrangone, Ornella Di Marco, Arianna Pasino, Gianfranco Stigliano, Alessio Mosca, Mauro Pettorruso, Fabrizio Schifano and Giovanni Martinotti description
  • Buvidal: is it really a ‘game changer’ in the treatment of problematic opioid use? (2023) Kate Holloway and Fabrizio Schifano
  • Editorial: Misuse and abuse of prescription drugs in custodial settings. (2023) Filippo Perani, Stefania Chiappini, Fabrizio Schifano and Arianna Giorgetti
  • Exploring the understanding, source of availability and level of access of cognitive enhancers among university students in the United Arab Emirates: a qualitative study. (2023) Safia Sharif, Suzanne Fergus, Amira Guirguis, Nigel Smeeton and Fabrizio Schifano picture_as_pdf
  • Self-medication with Novel Psychoactive Substances (NPS): A systematic review. (2023) Tayler J. Holborn, Robert Page, Fabrizio Schifano and Paulo Deluca picture_as_pdf
  • Stimulant and hallucinogenic novel psychoactive substances; an update. (2023) Fabrizio Schifano, Alessandro Vento, Norbert Scherbaum and Amira Guirguis
  • Exploring the Nexus of Binge Eating Disorder (BED), New Psychoactive Substances (NPS), and Misuse of Pharmaceuticals: Charting a Path Forward. (2023) Stefania Chiappini, G. Duccio Papanti Pelletier, Rachel Vickers-Smith, John Corkery, Amira Guirguis, Giovanni Martinotti and Fabrizio Schifano
  • GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. (2023) Davide Arillotta, Giuseppe Floresta, Amira Guirguis, John Martin Corkery, Valeria Catalani, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano
  • Opiate maintenance patients’ attitudes and self-reported adherence to protective measures against SARS-CoV-2 infections. (2023) Michael Specka, Tobias Kröckert, Mirko Trilling, Udo Bonnet, Fabrizio Schifano and Norbert Scherbaum
  • Obstacles to Treatment retention in Opioid Use Disorder: An International Substance Use Disorder Treatment Worker Survey. (2023) Matthew Jones, Amira Guirguis, Alan Watkins, Ceri Bradshaw, Lily Mohamed and Fabrizio Schifano description
  • No prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS). (2023) Tayler Holborn, Fabrizio Schifano and Paolo Deluca
  • An update on psychoactive substances: Pharmacology and Toxicology issues. (2023) Stefania Chiappini and Fabrizio Schifano description
  • Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. (2023) Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano
  • Handheld Raman Spectroscopy in the First UK Home Office Licensed Pharmacist-Led Community Drug Checking Service. (2023) Anthony Mullin, Mark Scott, Giorgia Vaccaro, Rosalind Gittins, Salvatore Ferla, Fabrizio Schifano and Amira Guirguis
  • In silico studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and de novo designer benzodiazepines. (2023) Valeria Catalani, Giuseppe Floresta, Michelle Botha, John Martin Corkery, Amira Guirguis, Alessandro Vento, Vincenzo Abbate and Fabrizio Schifano
  • Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? (2022) Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini and Giuseppina Cantarella
  • First death involving 4-Fluoroethylphenidate (4F-EPH): case-report, user experiences, and review of the related literature. (2022) John Martin Corkery and Fabrizio Schifano picture_as_pdf
  • Recreational Drug Misuse and Its Potential Contribution to Male Fertility Levels’ Decline: A Narrative Review. (2022) Nicolò Schifano, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Paolo Capogrosso, Federico Dehò, Giovanni Martinotti and Fabrizio Schifano
  • Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction-Volume II. (2022) Stephania Chiappini, Fabrizio Schifano and Giovanni Martinotti picture_as_pdf
  • Knowledge and use of over-the-counter drugs in Italy: a survey-based study in the general population. (2022) Stephania Chiappini, Franca Ceci, Alessio Mosca, Francesco Di Carlo, Julius Burkauskas, Mauro Pettorruso, Giovanni Martinotti, Amira Guirguis, John Martin Corkery, Norbert Scherbaum, Fabrizio Schifano and Massimo di Giannantonio
  • Alprazolam-related deaths in Scotland, 2004-2020. (2022) John Martin Corkery, Amira Guirguis, Stefania Chiappini, Giovanni Martinotti and Fabrizio Schifano picture_as_pdf
  • Designer Benzodiazepines’ Activity on Opioid Receptors: A Docking Study. (2022) Valeria Catalani, Michelle Botha, John Martin Corkery, Amira Guirguis, Alessandro Vento and Fabrizio Schifano
  • Contribution of drugs to drownings in Scotland, 1996-2020. (2022) John Corkery, Giovanni Martinotti and Fabrizio Schifano
  • Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment. (2022) Michael Specka, Thomas Kuhlmann, Udo Bonnet, Jürgen Sawazki, Luzia Schaaf, Stefan Kühnhold, Renate Steinert, Torsten Grigoleit, Helmut Eich, Benita Zeiske, Antje Niedersteberg, Katharina Steiner, Fabrizio Schifano and Norbert Scherbaum picture_as_pdf
  • Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). (2022) Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John M. Corkery, Giovanni Martinotti, Daniel R. Harris and Fabrizio Schifano
  • Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. (2022) Nicolo Schifano, Paolo Cappogrosso, Luca Boeri, Guiseppe Fallara, Stefania Chiappini, Matthew Rewhorn, Omer Onur Cakir, Hannah Harvey, Fabio Castiglione, Hussain Alnajjar, Asif Muneer, Frederico Deho, Fabrizio Schifano, Francesco Montorsi and Andrea Salonia
  • A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. (2022) Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John Martin Corkery, Giovanni Martinotti and Fabrizio Schifano
  • Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. (2022) Fabrizio Schifano, Valeria Catalani, Safia (Sophia) Sharif, Flavia Napoletano, John Corkery, Davide Arillotta, Suzanne Fergus, Alessandro Vento and Amira Guirguis
  • Misuse of anticholinergic medications: a systematic review. (2022) Stefania Chiappini, Alessio Mosca, Andrea Miuli, Francesco Semeraro, Gianluca Mancusi, Maria Chiara Santovito, Francesco Di Carlo, Mauro Pettorruso, Amira Guirguis, John M. Corkery, Giovanni Martinotti, Fabrizio Schifano and Massimo di Giannantonio picture_as_pdf
  • Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study. (2022) Safia Sharif, Suzanne Fergus, Amira Guirguis, Nigel Smeeton and Fabrizio Schifano
  • New Access Routes to Undertreated Populations; How Do Problem Substance Users Recruited from An Unemployment office Differ from Drug Detoxification Treatment Inpatients? (2021) Norbert Scherbaum, Thomas Mikoteit, Lilia Witkowski, Udo Bonnet, Michael Specka, Fabrizio Schifano and Bodo Lieb
  • Knowledge and Use of Novel Psychoactive Substances in Italy: a Survey-Based Study in the General Population. (2021) Caroline Zangani, Edoardo Giuseppe Ostinelli, Barbara Giordano, Armando D’Agostino, Giovanni Martinotti, Massimo Clerici, Orsola Gambini and Fabrizio Schifano
  • Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019. (2021) John Martin Corkery, Wang-Chu Hung, Hugh Claridge, Christine Goodair, Caroline S. Copeland and Fabrizio Schifano picture_as_pdf
  • Worsening of the Toxic Effects of (±) Cis -4,4′-DMAR Following Its Co-Administration with (±) Trans -4,4′-DMAR: Neuro-Behavioural, Physiological, Immunohistochemical and Metabolic Studies in Mice. (2021) Micaela Tirri, Paolo Frisoni, Sabrine Bilel, Raffaella Arfè, Claudio Trapella, Anna Fantinati, Giorgia Corli, Beatrice Marchetti, Fabio De-Giorgio, Cristian Camuto, Monica Mazzarino, Rosa Maria Gaudio, Giovanni Serpelloni, Fabrizio Schifano, Francesco Botrè and Matteo Marti
  • Psychonauts’ psychedelics: a systematic, multilingual, web-crawling exercise. (2021) Valeria Catalani, John Martin Corkery, Amira Guirguis, Flavia Napoletano, Davide Arillotta, Caroline Zangani, Alessandro Vento and Fabrizio Schifano
  • The psychonauts’ benzodiazepines; quantitative structure-activity relationship (QSAR) analysis and docking prediction of their biological activity. (2021) Valeria Catalani, Michelle Botha, John Martin Corkery, Amira Guirguis, Alessandro Vento, Norbert Scherbaum and Fabrizio Schifano description
  • Covid-19 pandemic impact on substance misuse: a social media listening, mixed method analysis. (2021) Davide Arillotta, Amira Guirguis, John Martin Corkery, Norbert Scherbaum and Fabrizio Schifano
  • Club Drugs and Psychiatric Sequelae: An Issue of Vulnerability and Previous Psychiatric History. (2021) Giovanni Martinotti, Cristina Merino Del Villar, Andrés Garcia Cordoba, Lluís Andrés Tubau, Ivan Castro Sánchez, Francesco Di Carlo, Stefania Chiappini, Mauro Pettorruso, Fabrizio Schifano and Massimo Di Giannantonio
  • The New Future Pharmacology Journal: A Cutting-Edge Opportunity for Rapidly Sharing and Widely Disseminating the Most Advanced Research Ideas and Findings. (2021) Fabrizio Schifano description
  • New Psychoactive Substances and suicidality: a systematic review of the current literature. (2021) Stefania Chiappini, Alessio Mosca, A. Miuli, Monica Chiara Santovito, Laura Orsolini, John Martin Corkery, Amira Guirguis, Mauro Pettorruso, Giovanni Martinotti, Massimo di Giannantonio and Fabrizio Schifano description
  • Focus on over-the-counter drugs’ misuse; a systematic review on antihistamines, cough medicines and decongestants. (2021) Fabrizio Schifano, Stefania Chiappini, Andrea Miuli, Monica Chiara Santovito, Alessio Mosca, Maria Chiara Santovito, John Martin Corkery, Amira Guirguis, Mauro Pettorruso, Massimo di Giannantonio and Giovanni Martinotti
  • New Psychoactive Substances (NPS) and Serotonin Syndrome onset: a Systematic Review. (2021) Fabrizio Schifano, Stephania Chiappini, John Corkery, Norbert Scherbaum, Flavia Napoletano, Davide Arillotta, Valeria Catalani, Alessandro Vento, Mauro Pettorruso, Giovanni Martinotti, Massimo di Giannantonio and Amira Guirguis
  • Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report. (2021) Stefania Bonaccorso, Angelo Ricciardi, Sophie Ouabbou, Christos Theleritis, Arabella Ross-Michealides, Antonio Metastasio, Neil Stewart, Marwa Mohammed and Fabrizio Schifano description
  • Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction. (2021) Stefania Chiappini, Fabrizio Schifano and Giovanni Martinotti
  • Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany. (2021) Norbert Scherbaum, Udo Bonnet, Henning Hafermann, Fabrizio Schifano, Stefan Bender, Torsten Grigoleit, Jens Kuhn, Peter Nyhuis, Ulrich W Preuss, Gerhard Reymann, Udo Schneider, Jo Shibata and Michael Specka
  • The e-psychonaut drugs’ psychopharmacology. (2021) Fabrizio Schifano, Stephania Chiappini, John Martin Corkery, Norbert Scherbaum and Amira Guirguis
  • Treatment of kratom use disorder with a classical tricyclic antidepressant: A case report and review. (2021) Alessandro Vento, Simone de Persis, Sergio De Filippis, Fabrizio Schifano, Flavia Napoletano, John Martin Corkery and Georgios D. Kotzalidis
  • The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. (2021) Safia Sharif, Amira Guirguis, Suzanne Fergus and Fabrizio Schifano
  • Opioid painkillers' dependence in a sample of elderly medical inpatients. (2021) Stephania Chiappini, Fabrizio Schifano, Giovanni Martinotti, Johanna Strasser, Udo Bonnet and Norbert Scherbaum
  • Identifying new/emerging psychoactive substances at the time of COVID-19; a web-based approach. (2021) Valeria Catalini, Davide Arillotta, John Martin Corkery, Amira Guirguis, Alessandro Vento and Fabrizio Schifano description
  • The benzydamine experience: A systematic review of Benzydamine abuse. (2021) Stephania Chiappini, Andrea Miuli, Alessio Mosca, Mauro Pettorruso, Amira Guirguis, John Martin Corkery, Giovanni Martinotti, Massimo di Giannantonio and Fabrizio Schifano
  • Beyond the Purple Drank. Study of promethazine abuse according to the European Medicines Agency (EMA) Adverse Drug Reactions (ADR) reports. (2021) Stefania Chiappini, Fabrizio Schifano, John Martin Corkery and Amira Guirguis
  • Prescription drugs misuse in “clubbers” and disco goers in Ibiza. (2020) Massimo di Giannantonio, Attilio Negri, Stefania Schiavone, Chiara Vannini, Mauro Pettorruso, Fabio Di Giorgio, Valeria Verrastro, Luigia Trabace, Mariangela Corbo, Rossella Gottardo, Cristian Camuto, Monica Mazzarino, Andrea Barra, Domenico De Berardis, Juan Iglesias Lopez, Cristina Merino del Villar, Fabrizio Schifano and Giovanni Martinotti
  • Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor? (2020) Benedikt Bernd Claus, Michael Specka, Heath MacAnally, Norbert Scherbaum, Fabrizio Schifano and Udo Bonnet description
  • Misuse of prescription and over-the-counter drugs to obtain illicit highs: how pharmacists can prevent abuse. (2020) Stefania Chiappini, Amira Guirguis, John Corkery and Fabrizio Schifano
  • What about drug checking? Systematic review and netnographic analysis of social media. (2020) Amira Guirguis, Isma Moosa, Rosalind Gittins and Fabrizio Schifano
  • High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. (2020) Norbert Scherbaum, Friedrich Seiffert, Fabrizio Schifano, Michael Specka, Udo Bonnet and Stefan Bender
  • What about “Pharming”? Issues Regarding the Misuse of Prescription and Over‐the‐Counter Drugs. (2020) Stefania Chiappini and Fabrizio Schifano
  • Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports. (2020) Nicolo Schifano, Stefania Chiappini, Fabio Castiglione, Andrea Salonia and Fabrizio Schifano
  • The psychonauts' world of cognitive enhancers. (2020) Flavia Napoletano, Fabrizio Schifano, John Martin Corkery, Amira Guirguis, Davide Arillotta, Caroline Zangani and Alessandro Vento picture_as_pdf
  • Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients. (2020) Giovanni Martinotti, Raffaele Giorgetti, Fabrizio Schifano and Massimo di Giannantonio
  • Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service. (2020) Amira Guirguis, Rosalind Gittins and Fabrizio Schifano
  • COVID-19: The hidden impact on mental health and drug addiction. (2020) Stefania Chiappini, Amira Guirguis, Ann John, John Corkery and Fabrizio Schifano description
  • Coming off prescribed psychotropic medications: insights from their use as recreational drugs. (2020) Fabrizio Schifano
  • Substance Related Exogenous Psychosis: a post-modern syndrome. (2020) Giovanni Martinotti, Luisa De Risio, Chiara Vannini, Fabrizio Schifano, Mauro Pettorruso and Massimo Di Giannantonio
  • Anabolic androgenic steroid abuse in the United Kingdom: An update. (2020) Carrie Mullen, Benjamin J Whalley, Fabrizio Schifano and Julien S Baker
  • Novel opioids: systematic web crawling within the e-psychonauts’ scenario. (2020) Davide Arillotta, Fabrizio Schifano, Flavia Napoletano, Caroline Zangani, Liam Gilgar, Amira Guirguis, John Martin Corkery, E Aguglia and alessandro vento
  • The Dynamic Environment of Crypto Markets: The Lifespan of New Psychoactive Substances (NPS) and Vendors Selling NPS. (2020) Fabrizio Schifano
  • Analyzing the Open/Deep Web to Better Understand the New/Novel Psychoactive Substances (NPS) Scenarios: Suggestions from CASSANDRA and NPS.Finder Research Projects. (2020) Fabrizio Schifano
  • Exploring the baseline knowledge and experience of healthcare professionals in the United Kingdom on Novel Psychoactive Substances. (2020) Amira Guirguis, Nigel Smeeton, Hadar Zaman, Anne-Marie Felice, Stephanie Bancroft, Rosalind Gittins, Gill Hawksworth, John Corkery and Fabrizio Schifano picture_as_pdf
  • The e-psychonauts’ ‘Spiced’ World; assessment of the synthetic cannabinoids’ information available online. (2020) Caroline Zangani, Fabrizio Schifano, Flavia Napoletano, Davide Arillotta, Liam Gilgar, Amira Guirguis, John Martin Corkery, Orsola Gambini and Alessandro Vento
  • Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of Novel Psychoactive Substances. (2020) Elena Deligianni, Omari-Jordan Daniel, John Corkery, Fabrizio Schifano and Lisa Lione description
  • Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA. (2020) Agnieszka Pisarska, Paolo Deluca, Zsolt Demetrovics, John Corkery, Jacek Moskalewicz, ReDNet Group, Ornella Corazza, John Corkery, Jacqueline Stair, Suzanne Fergus, Cinzia Pezzolesi and Fabrizio Schifano
  • Focus on clozapine withdrawal- and misuse-related cases, as reported to the European Medicines Agency (EMA) pharmacovigilance database. (2020) Stephania Chiappini, Fabrizio Schifano, John Martin Corkery and Amira Guirguis description
  • How deaths can help clinicians and policy-makers understand the risks of Novel Psychoactive Substances. (2020) John Corkery, Fabrizio Schifano and Giovanni Martinotti
  • 'New/Designer Benzodiazepines': an analysis of the literature and psychonauts’ trip reports. (2020) Laura Orsolini, John Corkery, Stephania Chiappini, Amira Guirguis, Alessandro Vento, Domenico De Berardis, Duccio Papanti and Fabrizio Schifano
  • Commentary on: Attafi IM, Albeishy MY, Oraiby ME, Khardali IA, Shaikhain GA, Fageeh MM. Postmortem Distribution of Cathinone and Cathine in Human Biological Specimens in a Case of Death Associated with Khat Chewing. Arab J Forensic Sci Forensic Med. 2018 Jun 7;1(7). (2019) John Corkery, Fabrizio Schifano and Amira Guirguis description
  • The use of new psychoactive substances (NPS) in young people and their role in mental health care : a systematic review. (2019) Laura Orsolini, Stephania Chiappini, John Corkery, Amira Guirguis, Duccio Papanti and Fabrizio Schifano
  • The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective. (2019) Laura Orsolini, Stephania Chiappini, Duccio Papanti, Domenico De Berardis, John Martin Corkery and Fabrizio Schifano description
  • The clinical challenges of synthetic cathinones. (2019) Fabrizio Schifano, Flavia Napoletano, Davide Arillotta, Caroline Zangani, Liam Gilgar, Amira Guirguis, John Corkery and Alessandro Vento
  • Characteristics of deaths associated with kratom use. (2019) John Corkery, Peter Streete, Hugh Claridge, Christine Goodair, Duccio G. Papanti, Laura Orsolini, Fabrizio Schifano, Kanav Sikka, Sophie Körber and Amy Hendricks
  • Cannabidiol (CBD) Use in Psychiatric Disorders; A Systematic Review. (2019) Stefania Bonaccorso, Angelo Ricciardi, Caroline Zangani, Stefania Chiappini and Fabrizio Schifano
  • New/emerging psychoactive substances and associated psychopathological consequences. (2019) Fabrizio Schifano, Flavia Napoletano, Stephania Chiappini, Amira Guirguis, John Corkery, Stefania Bonaccorso, Angelo Ricciardi, Norbert Scherbaum and alessandro vento
  • Dorsal Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: an 18F-FDG PET/CT Case Study. (2019) Lorenzo Moccia, Anna Tofani, Marianna Mazza, Marcello Covino, Giovanni Martinotti, Fabrizio Schifano, Luigi Janiri and Marco Di Nicola description
  • Pregabalin: a range of misuse-related unanswered questions. (2019) Fabrizio Schifano and Stephania Chiappini
  • New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues. (2019) Fabrizio Schifano, Flavia Napoletano, Stephania Chiappini, Laura Orsolini, Amira Guirguis, John Martin Corkery, Stefania Bonaccorso, Angelo Ricciardi, Norbert Scherbaum and alessandro vento
  • An Insight into Z-Drug Abuse and Dependence : An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. (2019) Fabrizio Schifano, Stefania Chiappini, John Martin Corkery and Amira Guirguis description
  • Assessing the 2004-2018 fentanyl misusing issues reported to an international range of adverse reporting systems. (2019) Fabrizio Schifano, Stephania Chiappini, John Corkery and Amira Guirguis picture_as_pdf
  • Recent changes in drug abuse scenarios : The new/novel psychoactive substances (NPS) phenomenon. (2018) Fabrizio Schifano
  • Patterns of management of patients with dual disorder (psychosis) in Italy: a survey of psychiatrists and other physicians focusing on clinical practice. (2018) Massimo Clerici, Andrea De Bartolomeis, Sergio De Filippis, Giuseppe Ducci, Icro maremmani, Giovanni Martinotti and Fabrizio Schifano description
  • Post-traumatic stress and substance misuse; neurobiological and clinical pharmacological correlates. (2018) Fabrizio Schifano, Gabriele Duccio Papanti, John Corkery and Laura Orsolini description
  • Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings : Clinical presentation and management issues. (2018) Stefania Bonaccorso, Antonio Metastasio, Angelo Ricciardi, Neil Stewart, Leila Jamal, Naasir Ud Dinn Rujully, Christos Theleritis, Stefano Ferracuti, Giuseppe Ducci and Fabrizio Schifano
  • Joint versus separate inpatient rehabilitation treatment for patients with alcohol use disorder or drug use disorder : an observational study. (2018) Stefan Bender, Michael Specka, Angela Buchholz, Frank Holscher, Fred Rist, Thomas Heinz, Fabrizio Schifano and Norbert Scherbaum description
  • Psychedelic Fauna for Psychonaut Hunters : A Mini-Review. (2018) Laura Orsolini, Michela Ciccarese, Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Corkery and Fabrizio Schifano picture_as_pdf
  • Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. (2018) Matteo Caloro, Giuseppa Calabrò, Eleonora de Pisa, Enrico Rosini, Georgios D Kotzalidis, Davide Lonati, Carlo Alessandro Locatelli, Pietro Papa, Fabrizio Schifano and Paolo Girardi picture_as_pdf
  • Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. (2018) Fabrizio Schifano, Stefania Chiappini, John Corkery and Amira Guirguis description
  • Exploration of the use of new psychoactive substances by individuals in treatment for substance misuse in the UK. (2018) Rosalind Gittins, Amira Guirguis, Fabrizio Schifano and Ian Maidment
  • Is there a potential of misuse for venlafaxine and bupropion? (2018) Fabrizio Schifano and Stephania Chiappini description
  • Is There a Potential of Misuse for Quetiapine? (2018) Stefania Chiappini and Fabrizio Schifano
  • Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances : A Comeback to the Shamanism? (2017) Laura Orsolini, Paul St John-Smith, Daniel McQueen, Duccio Papanti, John Corkery and Fabrizio Schifano
  • The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. (2017) Laura Orsolini, Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Corkery and Fabrizio Schifano
  • Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom communities associated with GHB and precursors. (2017) John M Corkery, Barbara Loi, Hugh Claridge, Christine Goodair and Fabrizio Schifano
  • An exploratory study of information sources and key findings on UK cocaine-related deaths. (2017) John Corkery, Hugh Claridge, Christine Goodair and Fabrizio Schifano
  • High Prevalence of Neuropathic Pain Component in Patients with Low Back Pain : Evidence from Meta-Analysis. (2017) Kapil Gudala, Dipika Bansal, Rambabu Vatte, Babita Ghai, Fabrizio Schifano and Chandrasehkar Boya
  • 4,4’-dimethylaminorex (‘4,4’-DMAR’; ‘Serotoni’) misuse; a web-based study. (2017) Barbara Loi, Mire Zloh, Maria Antonietta, John Corkery and Fabrizio Schifano
  • Can mobile phone technology support a rapid sharing of information on Novel Psychoactive Substances among health and other professionals internationally? (2017) Pierluigi Simonato, Francesco Saverio Bersani, Rita Santacroce, Eduardo Cinosi, Fabrizio Schifano, Giuseppe Bersani, Giovanni Martinotti and Ornella Corazza
  • From concept(ion) to life after death/the grave: the ‘natural’ history and life-cycle(s) of Novel Psychoactive Substances (NPS). (2017) Laura Orsolini, John Corkery, Duccio Papanti and Fabrizio Schifano
  • Intended and Unintended Use of Cathinone Mixtures. (2017) Amira Guirguis, John Corkery, Jacqueline Stair, Stewart Kirton, Mire Zloh and Fabrizio Schifano
  • An insight into the deep web; why it matters for addiction psychiatry? (2017) Laura Orsolini, Duccio Papanti, John Corkery and Fabrizio Schifano
  • A matter of life and death : substance-caused and substance-related fatalities in Ibiza in 2015. (2017) Rita Santacroce, Claudia Ruiz Bennasar, Juan Ramon Sancho Jaraiz, Federica Fiori, Fabiola Sarchione, Federica Angelini, Gabriella Catalano, Maria Luisa Carenti, John Martin Corkery, Fabrizio Schifano, Massimo di Giannantonio and Giovanni Martinotti
  • Is there a potential of misuse for Magnolia officinalis compounds/metabolites? (2017) Fabrizio Schifano, Valentina Guarino, Duccio G. Papanti, Jacopo Baccarin, Laura Orsolini and John M. Corkery
  • An international survey on the awareness, use, preference and health perception of Novel Psychoactive Substances (NPS). (2017) Elena Deligianni, John Corkery, Fabrizio Schifano and Lisa Lione
  • New Psychoactive Substances (NPS) - A Challenge for the Addiction Treatment Services. (2017) Norbert Scherbaum, F. Schifano and Udo Bonnet
  • Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders : A multicenter-observational study. (2017) Tiziano Acciavatti, Matteo Lupi, Rita Santacroce, Andrea Aguglia, Luigi Attademo, Laura Bandini, Paola Ciambrone, Giulia Lisi, Giovanni Migliarese, Federica Pinna, Diego Quattrone, Michele Ribolsi, Maria Salvina Signorelli, Salvatore Calò, Fabrizio Schifano, Massimo di Giannantonio and Giovanni Martinotti
  • Cannabis; epidemiological, neurobiological and psychopathological issues: an update. (2017) Maria Antonietta De Luca, Gaetano Di Chiara, Cristina Cadoni, Daniele Lecca, Laura Orsolini, Duccio Papanti, John Corkery and Fabrizio Schifano
  • Use of benzylglycinamide by a HIV-seropositive polysubstance user: : the changing pattern of novel psychoactive substance use among youths. (2016) Matteo Caloro, Giuseppa Calabro, Georgios D. Kotzalidis, Ilaria Cuomo, John Martin Corkery, Alessandro Emilio Vento, Luana Lionetto, Sergio De Filippis, Valentina Ranieri, Davide Lonati, Carlo Alessandro Locatelli, Eleonora de Pisa, Antonio Di Tommaso, Paolo Girardi and Fabrizio Schifano picture_as_pdf
  • Novel Psychoactive Substances: : the pharmacology of stimulants and hallucinogens. (2016) Fabrizio Schifano, Duccio Papanti, Laura Orsolini and John Corkery
  • A Decade of Gabapentinoid Misuse: : An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database. (2016) Stefania Chiappini and Fabrizio Schifano
  • Gli Psiconauti: navigatori della mente o sperimentatori chimici? (2016) Laura Orsolini, Roberta Vecchiotti, Duccio Papanti, Alessandro Valchera, John Corkery and Fabrizio Schifano picture_as_pdf
  • Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids : BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. (2016) Maria Antonietta De Luca, M. Paola Castelli, Barbara Loi, Alessandra Porcu, Mariella Martorelli, Cristina Miliano, Kathryn Kellett, Colin Davidson, Jacqueline L. Stair, Fabrizio Schifano and Gaetano Di Chiara
  • The characteristics of deaths involving kratom in the United Kingdom and elsewhere. (2016) John Corkery, Hugh Claridge, Christine Goodair, Duccio Papanti, Laura Orsolini, Sophie Koerber and Fabrizio Schifano picture_as_pdf
  • The consequences of drug misuse on post-marketing surveillance. (2016) Fabrizio Schifano, Duccio Papanti, Laura Orsolini and John Corkery picture_as_pdf
  • Novel psychoactive substances. (2016) Laura Orsolini, Duccio Papanti, Roberta Vecchiotti, Alessandro Valchera, John Corkery and Fabrizio Schifano picture_as_pdf
  • A systematic review of the nature of dispensing errors in hospital pharmacies. (2016) Khalid Aldhwaihi, Fabrizio Schifano, Cinzia Pezzolesi and Nkiruka Umaru
  • The potential utility of some legal highs in CNS disorders. (2016) Colin Davidson and Fabrizio Schifano picture_as_pdf
  • Deaths of individuals aged 16-24 years in the UK after using mephedrone. (2015) Barbara Loi, John Corkery, Hugh Claridge, Christine Goodair, Stephania Chiappini, Carla Gimeno Clemente and Fabrizio Schifano
  • Methoxetamine-related deaths in the UK : an overview. (2015) Stephania Chiappini, Hugh Claridge, John Corkery, Christine Goodair, Barbara Loi and Fabrizio Schifano
  • Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. (2015) Laura Orsolini, Giulia Francesconi, Duccio Papanti, Arianna Giorgetti and Fabrizio Schifano
  • Venlafaxine as the ‘baby ecstasy’? : Literature overview and analysis of web-based misusers’ experiences. (2015) Giulia Francesconi, Laura Orsolini, John Corkery, Duccio Papanti and Fabrizio Schifano picture_as_pdf
  • Olanzapine as the ideal ‘trip terminator’? : Analysis of online reports relating to antipsychotics’s use and misuse following occurance of novel psychoactive substance-related psychotic symptoms. (2015) Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani, Claudia Melcore, Antonio Metastasio, Giuseppe Bersani and Fabrizio Schifano picture_as_pdf
  • Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. (2015) Amira Guirguis, John Corkery, Jacqueline Stair, Stewart Kirton, Mire Zloh, Christine Goodair, Fabrizio Schifano and Colin Davidson
  • Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4 butanediol (1,4-BD; BDO) : a literature review with a focus on UK fatalities related to non-medical use. (2015) John Corkery, Barbara Loi, Hugh Claridge, Christine Goodair, Ornella Corazza, Simon Elliott and Fabrizio Schifano
  • Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012). (2015) Dipika Bansal, Anil Bhagat, Fabrizio Schifano and Kapil Gudala
  • Mind Navigators of Chemicals' Experimenters? A Web-Based Description of E-Psychonauts. (2015) Laura Orsolini, Gabriele Duccio Papanti, Giulia Francesconi and Fabrizio Schifano picture_as_pdf
  • Novel psychoactive substances of interest for psychiatry. (2015) Fabrizio Schifano, Laura Orsolini, Duccio Papanti and John Corkery
  • The “Eyeballing” technique : an emerging and alerting trend of alcohol misuse. (2015) Saverio Bersani, Ornella Corazza, G. Albano, S. Bruschi, A. Minichino, R. Vicinanza, Giuseppe Bersani, Giovanni Martinotti and Fabrizio Schifano
  • The diffusion of Performance and Image Enhancing Drugs (PIEDs) on the internet : The abuse of the cognitive enhancer Piracetam. (2014) Ornella Corazza, Saverio Bersani, Roberto Brunoro, G. Valeriani, Giovanni Martinotti and Fabrizio Schifano
  • A systematic review of counterfeit and substandard medicines in field quality surveys. (2014) Abdulaziz Alghannam, Zoe Aslanpour, Sara Evans and Fabrizio Schifano
  • Substance use in the club scene of Rome : a pilot study. (2014) Alessandro Vento, Giovanni Martinotti, Eduardo Cinosi, Matteo Lupi, Tiziano Acciavatti, Dario Carrus, Rita Santacroce, Eleonora Chillemi, Ludovica Bonifaci, Massimo di Giannantonio, Ornella Corazza and Fabrizio Schifano
  • 25C-NBOMe: preliminary data on pharmacology, psychoactive effects and toxicity of a new potent hallucinogenic drug. (2014) Francesco Saverio Bersani, Ornella Corazza, Gabriella Albano, Giuseppe Valeriani, Rita Santacroce, Flamina Bolzan, Eduardo Cinosi, Pierluigi Simonato, Giovanni Martinotti, Giuseppe Bersani and Fabrizio Schifano
  • Sexual enhancement products for sale online : raising awareness of the psychoactive effects of Yohimbine, Maca, Horny Goat Weed and Ginkgo Biloba. (2014) Ornella Corazza, Giovanni Martinotti, Rita Santacroce, E. Chilemi, Fabrizio Schifano and S. Cellek
  • "Spice", "Kryptonite", "Black Mamba": An overview of brand names and marketing stragtegies of Novel Psychoactive Substances on the Web. (2014) Ornella Corazza, G. Valeriani, F. S. Bersani, John Corkery, Giovanni Martinotti, Giuseppe Bersani and Fabrizio Schifano
  • Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. (2013) A.E. Vento, Fabrizio Schifano, Federica Gentili, Francesco Pompei, John Corkery, Georgios D. Kotzalidis and Paolo Girardi picture_as_pdf
  • Drops of Madness? : Recreational misuse of Tropicamide collyrium: early warning alerts from Russia and Italy. (2013) Saverio Bersani, Ornella Corazza, Pierluigi Simonato, Raffaele Lovaste, Linda Levari, A Mylokosta and Fabrizio Schifano picture_as_pdf
  • Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances (NPS) in the EU : the outcomes of the ReDNet project. (2013) Ornella Corazza, Sulaf Assi, Pierluigi Simonato, John Corkery, Saverio Bersani, Zsolt Demetrovics, Jacqueline Stair, Suzanne Fergus, Cinzia Pezzolesi, Manuela Pasinetti, Paolo Deluca, C. Drummond, Ursula Blaszko, Jacek Moskalewicz, Barbara Mervo, Lucia Di Furia, Magi Farre, Liv Flesland, Agnieszka Pisarska, Harry Shapiro, Holger Siemann, Arvid Skutle, Elias Sferrazza, Marta Torrens, Farran Sambola, Peer van der Kreeft, Norbert Scherbaum and Fabrizio Schifano
  • From "Special K" to "Special M" : The Evolution of the Recreational use of Ketamine and Methoxetamine. (2013) Ornella Corazza, Sulaf Assi and Fabrizio Schifano
  • Novel Psychoactive Substances (NPS) : a Study on Persian Language Websites. (2013) Imanollah Bigdeli, Ornella Corazza, Zoe Aslanpour and Fabrizio Schifano
  • The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) : A brief review. (2012) John Corkery, E. Durkin, S. Elliott, Fabrizio Schifano and A. Hamid Ghodse
  • Statin Use and Risk of Prostate Cancer : A Meta-Analysis of Observational Studies. (2012) Dipika Bansal, Krishna Undela, Sanjay D'Cruz and Fabrizio Schifano
  • Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, meow meow) in the United Kingdom. (2012) Fabrizio Schifano, John Corkery and A.Hamid Ghodse picture_as_pdf
  • Impact of community pharmacy diabetes monitoring and education programme on diabetes management : a randomised controlled study. (2012) Majid Ali, Fabrizio Schifano, Paul Robinson, G. Phillips, L. Doherty, P. Melnick, L. Laming, A. Sinclair and S. Dhillon picture_as_pdf
  • Does clinical handover promote situation awareness? : Implications for person-centered healthcare. (2012) Cinzia Pezzolesi, Tanya Manser, Fabrizio Schifano, Andrzej Kostrzewski, John Pickles, Harriet Nicholls, Daniel Fishman, Arshad Mubarik and S. Dhillon picture_as_pdf
  • 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) : A preliminary review. (2012) John Corkery, Fabrizio Schifano, A. Hamid Ghodse, S. Elliott and Ornella Corazza
  • Identifying emerging trends in recreational drug use : outcomes from the Psychonaut Web Mapping Project. (2012) Paolo Deluca, Zoe Davey, Ornella Corazza, Manuela Pasinetti, C. Pezzolesi, Fabrizio Schifano, Lucia Di Furia, Magi Farre, Marta Torrens, Liv Flesland, Arvid Skutle, E. Iversen, Miia Mannonen, A. Majava, Teuvo Peltoniemi, Norbert Scherbaum, Holger Siemann and Peer van der Kreeft picture_as_pdf
  • Phenomenon of new drugs on the Internet : the case of ketamine derivative methoxetamine. (2012) Ornella Corazza, Fabrizio Schifano, Pierluigi Simonato, Suzanne Fergus, Sulaf Assi, Jacqueline Stair, John Corkery, Giuseppina Trincas, Paolo Deluca, Zoe Davey, Ursula Blaszko, Zsolt Demetrovics, Jacek Moskalewicz, Aurora Enea, Giuditta di Melchiorre, Barbara Mervo, Lucia Di Furia, Magi Farre, Liv Flesland, Manuela Pasinetti, Cinzia Pezzolesi, Agnieszka Pisarska, Harry Shapiro, Holger Siemann, Arvid Skutle, Aurora Enea, Giuditta di Melchiorre, Elias Sferrazza, Marta Torrens, Peer van der Kreeft, Daniela Zummo and Norbert Scherbaum picture_as_pdf
  • Mephedrone, new kid for the chop? (2011) Adam R. Winstock, Luke R. Mitcheson, Paolo Deluca, Zoe Davey, Ornella Corazza and Fabrizio Schifano picture_as_pdf
  • 'Bundle of fun' or 'bunch of problems'? : Case series of khat-related deaths in the UK. (2011) John Corkery, Fabrizio Schifano, Adenekan Oyefeso, A. Hamid Ghodse, Thomy Tonia, Vinesha Naidoo and Jennifer Button picture_as_pdf
  • Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997 - 2007. (2011) G. Zamparutti, Fabrizio Schifano, John Corkery, A. Oyefeso and A. Hamid Ghodse picture_as_pdf
  • Designer drugs on the Internet : a phenomenon out-of-control? : The emergence of hallucinogenic drug Bromo-Dragonfly. (2011) Ornella Corazza, Fabrizio Schifano, Magi Farre, Paolo Deluca, Zoe Davey, Colin Drummond, Marta Torrens, Zsolt Demetrovics, Lucia Di Furia, Liv Flesland, Barbara Mervo, Jacek Moskalewicz, Agnieszka Pisarska, Harry Shapiro, Holger Siemann, Arvid Skutle, Cinzia Pezzolesi, Peer van der Kreeft and Norbert Scherbaum
  • Emergence and identification of new products of designer drug products from the internet. (2011) Sulaf Assi, Suzanne Fergus, Jacqueline Stair, Ornella Corazza and Fabrizio Schifano picture_as_pdf
  • Is there a recreational misuse potential for Pregabalin? : Analysis of anecdotal online reports in comparison with related Gabapentin and Clonazepam data. (2011) Fabrizio Schifano, S. D'Offizi, M. Piccione, Ornella Corazza, P. Deluca, Z. Davey, G. di Melchiorre, L. DiFuria, M. Farre, L. Flesland, M. Mannonen, A. Majava, S. Pagani, T. Peltoniemi, H. Siemann, A. Skutle, M. Torrens, C. Pezzolesi, P. van der Kreeft and N. Scherbaum picture_as_pdf
  • Mephedrone (4-methylmethcathinone; 'meow meow') : chemical, pharmacological and clinical issues. (2011) Fabrizio Schifano, Antonio Albanese, Suzanne Fergus, Jacqueline Stair, Paolo Deluca, Ornella Corazza, Zoe Davey, John Corkery, Holger Siemann, Norbert Scherbaum, Magi' Farre', Marta Torrens, Zsolt Demetrovics and A. Hamid Ghodse picture_as_pdf
  • Overview of literature and information on "khat-related" mortality: a call for recognition of the issue and further research. (2011) John Corkery, Fabrizio Schifano, Adenekan Oyefeso, A. Hamid Ghodse, Thomy Tonia, Vinesha Naidoo and Jennifer Button
  • Suicide verdicts as opposed to accidental deaths in substance-related fatalities (UK, 2001–2007). (2011) A.E. Vento, M. Pompili, Fabrizio Schifano, John Corkery, M. Innamorati, P. Girardi and H. Ghodse picture_as_pdf
  • An introduction to the new phenomenon of Internet-based drugs. (2011) Harry Shapiro, Ornella Corazza, Pierluigi Simonato and Fabrizio Schifano picture_as_pdf
  • Clinical handover incident reporting in one UK general hospital. (2010) Cinzia Pezzolesi, Fabrizio Schifano, John Pickles, William Randell, Zakar Hussain, Helen Muir and S. Dhillon picture_as_pdf
  • Near-death states reported in a sample of 50 misusers. (2010) Ornella Corazza and Fabrizio Schifano picture_as_pdf
  • Overview of amphetamine-type stimulant mortality data – UK, 1997–2007. (2010) Fabrizio Schifano, John Corkery, Vinesha Naidoo, Adenekan Oyefeso and Hamid Ghodse
  • Two UK suicides using nicotine extracted from tobacco employing instructions available on the Internet. (2010) John Corkery, J. Button, A.E. Vento and Fabrizio Schifano
  • Is urbanization a risk factor for substance misuse? (2008) Fabrizio Schifano
  • Trapped in the "K-hole" : overview of deaths associated with ketamine misuse in the UK (1993-2006). (2008) Fabrizio Schifano, John Corkery, Adenekan Oyefeso, Thomy Tonia and Abdol Hamid Ghodse picture_as_pdf
  • The Gamblers' Temperament and Character Inventory (TCI) Personality Profile. (2007) L. Janiri, G. Martinotti, T. Dario, Fabrizio Schifano and P. Bria
  • Smokable ( ice , crystal meth ) and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK. (2007) Fabrizio Schifano, John Corkery and G. Cuffolo
  • Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). (2006) Fabrizio Schifano, John Corkery, A. Oyefeso and A. Hamid Ghodse
  • Fatal injuries while under the influence of psychoactive drugs: a cross-sectional exploratory study in England. (2006) A. Oyefeso, Fabrizio Schifano, H. Ghodse, K. Cobain, R. Dryden and John Corkery
  • Review of Deaths Related to Analgesic- and Cough Suppressant-opioids; England and Wales 1996-2002. (2006) Fabrizio Schifano, G. Zamparutti, F. Zambello, A. Oyefeso, P. Deluca, M. Balestrieri, D. Little and A. Hamid Ghodse
  • Review of deaths related to taking ecstasy, England and Wales, 1997-2000. (2003) Fabrizio Schifano, A. Oyefeso, L. Webb, M. Pollard, John Corkery and A. Hamid Ghodse
  • Phenazepam abuse in the UK : an emerging problem causing serious adverse health problems, including death. (2012) John Martin Corkery, Fabrizio Schifano and Abdol Hamid Ghodse
  • Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. (2003) Fabrizio Schifano, A. Oyefeso, John Corkery, K. Cobain, R. Jambert-Gray, G. Martinotti and A. Hamid Ghodse
  • Editorial: Second International Conference on Novel Psychoactive Substances (NPSs) : Keynote Addresses and Conference Abstracts. (2013) Andy Parrott, Ornella Corazza, Fabrizio Schifano, Paul Griffiths, Roumen Sedevof, Ana Gallegos, Robin Murray, Zsolt Demetrovics, Val Curran, Giuseppe Bersani and L. Singer
  • The effects of methadone and its role in fatalities. (2004) John Corkery, Fabrizio Schifano, A. Hamid Ghodse and Adenekan Oyefeso
  • 5,6-Methylenedioxy-2-aminoindane : from laboratory curiosity to 'legal high'. (2012) C. T. Gallagher, S. Assi, J. L. Stair, S. Fergus, Ornella Corazza, John Corkery and Fabrizio Schifano
  • Burnout, coping and job satisfaction in service staff treating opioid addicts : from Athens to Zurich. (2010) R. Volker, B. Bernhard, A. Kokkevi, Fabrizio Schifano, R. Room, J. Palm, R. Stohler, L. DiFuria, J. Rehm, F. Holscher and C. Schwarzer
  • Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990-2004). (2008) Fabrizio Schifano and John Corkery
  • Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. (2011) Michael Specka, Udo Bonnet, Martin Heilmann, Fabrizio Schifano and Norbert Scherbaum
  • Legal highs: safe and legal heavens? : A study on the diffusion, knowledge and risk awareness of novel psychoactive drugs among students in the UK. ["Legal highs": paradisi sicuri e legali? Uno studio sulla diffusione, conoscenza e consapevolezza del rischio delle nuove droghe psicoattive tra gli studenti del Regno Unito]. (2014) Ornella Corazza, Pierluigi Simonato, John Corkery, Giuseppina Trincas and Fabrizio Schifano
  • E-Psychonauts : Conducting research in online drug forum communities. (2012) Zoe Davey, Paolo Deluca, Fabrizio Schifano and Ornella Corazza
  • 'Legal highs' an inappropriate term for 'Novel Psychoactive Drugs' in drug prevention and scientific debate. (2012) Ornella Corazza, Fabrizio Schifano, Zsolt Demetrovics and W. van den Brink
  • Analisi dei report online relativi al potenziale uso errato della benzidamina Analysis of online reports on the potential misuse of benzidamine. (2013) Fabrizio Schifano, Ornella Corazza, Alessandro Marchi, Giuditta di Melchiorre, Elias Sferrazza, Aurora Enea, Z. Davey, Ursula Blaszko and Paolo Deluca
  • Nuove sostanze d'abuso sul Web : Il ruolo dello Psychonaut Web Mapping Project. (2010) Fabrizio Schifano, Ornella Corazza, A. Ricciardi, C. Rafanelli, P. Deluca, Z. Davey, L. Di Furia, M. Farrè, L. Flesland, M. Mannonen, T. Peltoniemi, C. Pezzolesi, S. Pagani, N. Scherbaum, H. Siemann, A. Skutle, M. Torrens and P. Van Der Kreeft
  • Az elektronikus prevenció lehetőségei az új (szintetikus) drogok használatának megelőzésében : a Rekreációs Drogok Európai Hálózatának (Recreational Drugs European Network) bemutatása. (2010) Zsolt Demetrovics, Barbara Mervo, Ornella Corazza, Zoe Davey, Paolo Deluca, C. Drummond, Aurora Enea, Jacek Moskalewicz, G. Di Melchiorre, Lucia Di Furia, Liv Flesland, Luciano Floridi, F. Iszaj, Norbert Scherbaum, Holger Siemann, Arvid Skutle, Marta Torrens, Manuela Pasinetti, Cinzia Pezzolesi, Agnieszka Pisarska, Harry Shapiro, Elias Sferrazza, Peer van der Kreeft and Fabrizio Schifano
  • Mass-information : Mephedrone, myths, and the new generation of legal highs. (2010) Zoe Davey, Ornella Corazza, Fabrizio Schifano and Paolo Deluca
  • Psychoactive drug or mystical incense? : Overview of the online available information on Spice products. (2010) Fabrizio Schifano, Ornella Corazza, Paolo Deluca, Zoe Davey, Di Furia Lucia, Magi Farre, Liv Flesland, Miia Mannonen, Stefania Pagani, Teuvo Peltoniemi, Cinzia Pezzolesi, Norbert Scherbaum, Holger Siemann, Arvid Skutle, Marta Torrens and Peer van der Kreeft
  • Pregabalin misuse-related issues; Intake of large dosages, drug-smoking allegations, and possible association with myositis : Two case reports. (2012) D. Carrus and Fabrizio Schifano
  • Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. (2014) Ornella Corazza, Sulaf Assi, S. Malekianragheb, M Beni, Iman Bigdeli, Zoe Aslanpour and Fabrizio Schifano
  • Can reinforcement-based interventions to reduce drug use successfully be adapted to routine opioid maintenance treatment? (2013) Michael Specka, Antje Öning, Jürgen Kluwig, Fabrizio Schifano, Markus Banger, Wolfgang Lange, Hildegard Lax, Bärbel Marrziniak, Claudia Schüngel and Norbert Scherbaum
  • Le nuove sostanze psicoattive: problematiche cliniche e farmacologiche The novel psychoactive substances: clinical and pharmacological issues. (2016) Fabrizio Schifano, Laura Orsolini, Duccio Papanti and John Corkery
  • “Legal highs” on the net—evaluation of UK-based websites, products and product information. (2010) M.M. Schmidt, A. Sharma, Fabrizio Schifano and C. Feinmann
  • Buprenorphine mortality, seizures and prescription data in the UK, 1980-2002. (2005) Fabrizio Schifano, John Corkery, Eilish Gilvarry, Paolo Deluca, Adenekan Oyefeso and A. Hamid Ghodse
  • New trends in the cyber and street market of recreational drugs? : The case of 2C-T-7 ('Blue Mystic'). (2005) Fabrizio Schifano, Paolo Deluca, Lisa Agosti, Giovanni Martinotti, John Corkery, Baldacchino Alex, Bonan Caterina, Bothas Heikki, Brigada Raffaella, Comacchio Anna, Di Furia Lucia, Duarte Rui Eastwood Dorte, Farré Magi, Ferreira Susana, Flores Irene, Guionnet Claude, Harder Lisbet, Stokholm Jensen Lene, Leoni Mauro, Littlejohn Christopher, Majava Aino, Peltoniemi Teuvo, Pizza Milena, Rawaf Salman, Robert Damien, Rossi Maria Angela, Rovetto Francesco, Scherbaum Norbert, Siemann Holger, Tarrago Josep, Torrens Marta, Zambello Francesco and Psychonaut 2002 Research Group
  • Novel psychoactive substances as a new challenge for health professionals : results of a survey carried out in Italy. (2013) Pierluigi Simonato, Ornella Corazza and Fabrizio Schifano
  • MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity : a brief overview and update. (2013) John Corkery, Simon Elliott, Fabrizio Schifano, Ornella Corazza and Abdol Hamid Ghodse
  • Nowe substancje psychoaktywne : potrzeby informacyjne młodzieży I profesjonalistów New psychoactive substancesthe youth and professionals informational needs. (2013) Agnieszka Pisarska, Jacek Moskalewicz, Ornella Corazza, Sulaf Assi, Pierluigi Simonato, John Corkery, Zsolt Demetrovics, Jacqueline Stair, Suzanne Fergus, Cinzia Pezzolesi, Manuela Pasinetti, Paolo Deluca, Colin Drummond, Ursula Blaszko, Barbara Mervo, Lucia Di Furia, Magi Farre, Liv Flesland, Harry Shapiro, Holger Siemann, Arvid Skutle, Marta Torrens, Farran Sambola, Peer van der Kreeft, Norbert Scherbaum and Fabrizio Schifano
    • Book Section
  • Synthetic Cannabinoids, the largest and most diverse group of novel psychoactive substances. (2024) P G Duccio Papanti, Laura Orsolini, John Martin Corkery, Stefania Chiappini, Amira Guirguis, Alessando Vento and Fabrizio Schifano picture_as_pdf
  • Dipendenze farmacologiche e comportamentali. (2021) Fabrizio Schifano
  • Substance Use Disorders and Violence. (2020) Fabrizio Schifano, Caroline Zangani, Stephania Chiappini, Amira Guirguis, Stefania Bonaccorso and John Corkery description
  • Synthetic cathinones – prevalence and motivations for use. (2018) John Corkery, Amira Guirguis, Duccio Papanti, Laura Orsolini and Fabrizio Schifano
  • NPS: Medical Consequences Associated with Their Intake. (2016) Fabrizio Schifano, Laura Orsolini, Duccio Papanti and John Corkery description
  • Mephedrone-related fatalities in the United Kingdom : contextual, clinical and practical issues. (2012) John Corkery, Fabrizio Schifano and Abdol H Ghodse
  • Decessi ed altri indicatori chiave del consume di cocaine nel Regno Unito (1990-2004). (2006) Fabrizio Schifano and John Corkery picture_as_pdf
    • Monograph
  • Drug-related deaths in the UK: Annual Report 2011 [January-December 2010] : Drug-related deaths reported by Coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; Police forces in Scotland; & the Northern Ireland Statistics and Research Agency. (2012) A. Hamid Ghodse, John Corkery, Fabrizio Schifano, Antonio Piolanti, Giuseppina Trincas and Giuditta Di Melchiorre
  • Trends in UK deaths associated with abuse of volatile substances, 1971-2009. (2012) A. Hamid Ghodse, John Corkery, Kapil Ahmed and Fabrizio Schifano
    • Conference or Workshop Item
  • Novel Psychoactive Substance (NPS) awareness, use and health perception following The UK Psychoactive Substances Act 2016. (2017) Elena Deligianni, Omari-Jordan Daniel, John Corkery, Fabrizio Schifano and Lisa Lione
  • An evaluation of the types and contributing factors of dispensing errors in hospital pharmacy. (2016) Khalid Aldhwaihi, Fabrizio Schifano, Cinzia Pezzolesi and Nikkie Umaru
    • Other
  • An investigation into the relationship(s) between the different chemical classes of synthetic cathinones and their effects: desired, adverse and toxic. (2017) John Corkery, Amira Guirguis, Laura Orsolini, Duccio Papanti and Fabrizio Schifano
  • Substance use and misuse - Legal highs. (2016) Amira Guirguis, Rosalind Gittins, John Corkery and Fabrizio Schifano picture_as_pdf
  • The Unregulated Psychoactive Compound: ‘Benzo Fury’. (2013) Carla Gimeno Clemente, Stephania Chiappini, Hugh Claridge, John Corkery, Christine Goodair, Barbara Loi and Fabrizio Schifano
  • Consciousness, Drugs and the Internet. (2009) Ornella Corazza and Fabrizio Schifano
  • Drug-related deaths in the UK : Annual Report 2012. (2013) A. Hamid Ghodse, John Corkery, Hugh Claridge, Christine Goodair and Fabrizio Schifano
  • Drug-related deaths in the UK: January-December 2012 : Annual report 2013. (2014) John Corkery, Hugh Claridge, Barbara Loi, Christine Goodair and Fabrizio Schifano
  • UK deaths associated with ‘Z’ drugs (Zopiclone, Zolpidem & Zaleplon). (2013) Salvatore Casula, Hugh Claridge, John Corkery, Carla Gimeno Clemente, Christine Goodair, Barbara Loi and Fabrizio Schifano
  • Technologies and Lifestyles : how the Internet has revolutionized the drug market and people’s lives. (2017) Ornella Corazza, Francesco Saverio Bersani, Giuseppe Valeriani and Fabrizio Schifano
  • Development and evaluation of a Handover Performance Tool (HPT) for medical shift handovers. (2011) Cinzia Pezzolesi, S. Dhillon, Fabrizio Schifano, Andrzej Kostrzewski, John Pickles and Tanya Manser
  • Impact of community pharmacy diabetes monitoring and education programme on diabetes management : a randomised controlled study. (2011) Majid Ali, Fabrizio Schifano, Paul Robinson, G. Phillips, L. Doherty, P. Melnick, L. Laming, A. Sinclair and S. Dhillon
  • Impact of community pharmacy monitoring programme on diabetes-related outcomes in primary care. (2009) Fabrizio Schifano, S. Dhillon, G. Phillips, Majid Ali, V. Jagessar and Paul Robinson
  • Fatalities Associated with Mephedrone in Combination with Other Stimulant Drugs in Young People Aged 16-24 Years. (2013) Barbara Loi, Stephania Chiappini, Hugh Claridge, John Corkery, Carla Gimeno Clemente, Christine Goodair and Fabrizio Schifano
  • ‘Special M’ related fatalities in the UK. (2014) Stephania Chiappini, Hugh Claridge, John Corkery, Christine Goodair, Barbara Loi and Fabrizio Schifano
  • The evolution and characteristics of UK deaths involving GHB and its analogues. (2014) John Corkery, Barbara Loi, Hugh Claridge, Christine Goodair, Ornella Corazza, Simon Elliott and Fabrizio Schifano
  • Factors Impacting on the Evolution and Characteristics of UK Deaths Involving‘Traditional’ and ‘New’ Stimulants. (2013) John Corkery and Fabrizio Schifano
  • Methoxetamine: An Analogue of Ketamine. (2013) Stephania Chiappini, Hugh Claridge, John Corkery, Carla Gimeno Clemente, Christine Goodair, Barbara Loi and Fabrizio Schifano
    • This list was generated on Wed Nov 11 02:51:29 2026 GMT.